Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Greg Spendjian who wrote (264)	2/20/1998 6:01:00 PM
From: Joe Stephenson	Read Replies (1) \| Respond to of 1321

This previous posting is a good example of why QLT is likely a better investment opportunity than Miravant. While Miravant is mired in Phase I/II studies with AMD and their drug, QLT is well beyond that stage, and by the fall of this year should be reporting results from Phase III studies. There could be an FDA approval in this area by this time next year. It looks like QLT has about a 1-2 year head start on Miravant in AMD trials. The press release referred to Miravant holding Phase II/III INVESTIGATIONAL STUDIES, starting this spring. QLT is already 8 months into their Phase III. It is interesting that both Miravant and QLT are reporting similarly positive results from their early testing in this AMD research. Now will someone please explain why Miravant trades at a much higher price than QLT, when QLT has such a head start on this and other Photodynamic related reseach...ie. different applications for Cancer. Any thoughts?